Fourteen days. That’s the gap between President Trump’s trust purchasing between $1 million and $5 million in Axon Enterprise stock on Feb. 10 and ICE posting a notice on Feb. 24 seeking a five-year, $220 million Taser contract for roughly 17,800 new devices. That purchase would quadruple ICE’s current inventory of about 4,300 units. The ICE document’s specifications — a 45-foot range, 10 individually targeted probes — match only Axon’s Taser 10, according to procurement reviewers cited by CNBC. No contract has been awarded. No law was broken. The sequence would strain credulity in a political thriller.
A Contract Written for One Company
ICE’s procurement notice named Axon’s T10 as the upgrade target — because no competitor makes anything like it.
The notice didn’t just favor Axon. It explicitly referenced upgrading to the “T10” to replace aging X26P and X2 models — both Axon products. Axon manufactures approximately 90% of U.S. Tasers, according to investment firm Brown Advisory cited by CNBC. Competitors weren’t realistically in the running.
The company already holds a $370 million DHS body-camera contract awarded in 2023. It has received about $16.7 million in additional DHS contracts during Trump’s second term, according to NOTUS. Axon’s stock surged 34% in the week after ICE’s notice hit, and shares were up roughly 7% from Trump’s February 10 purchase date through June 26.
- Trump’s trust purchased $1M–$5M in Axon stock on Feb. 10, 2026; disclosed May 14 in a filing listing 3,700+ transactions
- ICE’s Feb. 24 RFI sought ~17,800 new Tasers plus unlimited cartridges and training over five years — more than quadrupling its ~4,300-unit inventory
- No contract has been awarded; the RFI is not a formal solicitation
- Axon already holds a $370M DHS body-camera contract (awarded 2023) and received ~$16.7M in DHS contracts during Trump’s second term
- Axon’s stock surged 34% in the week after ICE’s notice; shares were up ~7% from Trump’s Feb. 10 purchase through June 26
“It is not smart to buy stock in a company that was impacted by the decisions you would be making at the agency.” — Deborah Fleischaker, former acting chief of staff at ICE, now at UnidosUS
The White House says there’s nothing here. Spokesperson Anna Kelly told CNBC “there are no conflicts of interest,” calling the scrutiny a “tired narrative.” Trump’s assets sit in a trust managed by his children, with trades executed by independent third-party firms through automated systems. Presidents are legally exempt from the main criminal conflict-of-interest statute covering most federal officials. That’s the legal reality — ethics watchdogs have a different read entirely.
The Appearance Problem Is the Problem
Ethics experts aren’t alleging a crime — they’re pointing at a system that makes the question impossible to dismiss.
Jordan Libowitz of Citizens for Responsibility and Ethics in Washington told reporters the concern is that Trump “bought into a company whose business could grow if his own administration expands immigration enforcement.” That’s not an allegation of direct wrongdoing. It’s a conflict-of-interest argument built entirely on timing and policy alignment.
“The timing raises red flags.” – Deborah Fleischaker, former acting chief of staff at ICE and now at UnidosUS, told CNBC the proximity of Trump’s trade to the ICE notice demands scrutiny — even if public information cannot prove impropriety. Cases of secretly tracking users illustrate how executive-branch technology overreach rarely emerges from a single incident.
Axon isn’t waiting for the ethics debate to resolve. The company spent nearly $2.5 million on lobbying in 2025 — its highest annual total — targeting body-camera mandates and digital evidence management for federal law enforcement. It hired Claudia Davidson from Palantir, where she spent over seven years building that company’s federal business, to lead Axon’s own federal expansion. President Joshua Isner told investors DHS contracts represent a “major opportunity.” The Taser deal, if awarded, is the foot in the door. Axon’s real money follows hardware purchases — cloud storage, AI tools, and evidence-management platforms that attach like a subscription tier you didn’t realize you’d agreed to.
The contract remains unawarded. No investigation is open. But Axon’s surveillance app ecosystem — Fusus real-time mapping, Ring doorbell integration, body-camera networks threading through federal enforcement infrastructure — is already operational. Whether this particular deal closes or not, Axon’s Washington bet is already compounding.
